New radiation regimen aims to cut prostate cancer treatment time

NCT ID NCT00809991

Completed Disease control Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 study tested a radiation therapy plan that gives a slightly higher dose each day over fewer sessions (16 days instead of the usual 8-9 weeks) for men with early-stage prostate cancer. The goal was to see if this shorter schedule is safe and effective, while also tracking quality of life and side effects. 91 men with low-risk prostate cancer participated, and researchers measured urinary, bowel, and sexual function over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: radiation therapy (hypofractionated, image-guided)
What this could lead to: If successful, this could offer a more convenient and equally effective radiation schedule for men with early-stage prostate cancer.
What could go wrong: This is a small Phase 2 study, so results may not apply to all patients. The higher daily dose could increase side effects like urinary or bowel issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALIZED ADENOCARCINOMA OF THE PROSTATE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate adenocarcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

The Johns Hopkins University School of Medicne

Baltimore, Maryland, 21231, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.